New data on the global economic impact and burden of preventable blindness and vision impairment

NovartisTo highlight the critical need for access to eye care and regular eye examinations, Novartis and its eye care division, Alcon, are introducing new data on World Sight Day, highlighting the economic impact and burden that blindness and vision impairment can have on societies and individuals across the globe. World Sight Day, held on October 9th, is a global initiative to help raise awareness and address the problem of preventable blindness and vision impairment worldwide.

Conducted by Novartis, The European Forum Against Blindness (EFAB) and Deloitte Access Economics, "The Cost and Burden of Eye Diseases and Preventable Blindness" study quantified the economic impact of vision loss by analyzing the top four eye diseases responsible for vision loss: glaucoma, diabetic retinopathy, cataracts, and wet age-related macular degeneration (AMD), which, in the EU alone, affects one in 10 people. The study also analyzed the cost-effectiveness of interventions to prevent them. A total of 14 countries were included in the study: Australia, Argentina, Denmark, France, Germany, Ireland, Italy, Mexico, Poland, Slovak Republic, Spain, Sweden, Switzerland and the UK.

Burden and Impact of Preventable Blindness
Eyes need to be regularly examined, as many eye diseases show no early symptoms or are slow to progress and, are often only detected after vision has been altered or lost. Due to these factors, blindness and vision impairment can be a considerable burden to individuals, families and societies, imposing severe physical, financial and quality-of-life limitations.

The analysis found that within the 14 countries studied, more than 350,000 healthy life years are lost due to cataracts, glaucoma, AMD and diabetic retinopathy, equaling more than 123 million workdays lost per year. In addition, the annual economic costs due to preventable vision impairment and blindness totaled more than 20 billion EUR.

Vision Impairment and Blindness Can Be Avoided
Investing in cost-effective interventions has a big impact on reducing the disease burden. Globally, more than 285 million people live with vision impairment and blindness.[1] But, more than 90% of vision problems can be prevented, treated or cured, provided patients have access to treatment.[1]

The analysis found that access to eye care, and early diagnosis and treatment for these eye conditions can have an enormous impact on reducing the disease burden and offset a significant amount of economic cost to society. For instance, screening for diabetic retinopathy, cataracts and AMD alone can offset economic costs by more than €6 billion EUR each year. To learn more about the economic costs and burden of preventable blindness and how it differs across the globe, visit www.globalcostofblindness.com.

Taking Care of Your Eyes at Every Age
A person's eye health is constantly changing as they age, with new needs and challenges at different times in life. Eyes at age three are much different than eyes at age 30 or 60. The eyes are also a good indicator of overall health. A range of illness can be detected through an eye examination, including diabetes, high blood pressure, heart disease, and even rare hereditary diseases.[2]

This year on World Sight Day, Alcon is helping people around the world learn about their eye health at every age by providing in-depth, downloadable digital materials intended to help encourage conversations about how to properly maintain eye health and visual function. These materials cover eye diseases and conditions starting at birth to age 60 and older.

About Alcon
Alcon, the global leader in eye care, provides innovative products that enhance quality of life by helping people worldwide see better. The three Alcon businesses - Surgical, Ophthalmic Pharmaceuticals and Vision Care - offer the widest spectrum of eye care products in the world. Alcon is the second largest division of the Novartis Group, with pro-forma sales of USD 10.5 billion in 2013. Headquartered in Fort Worth, Texas, USA, Alcon has more than 25,000 employees worldwide, operations in 75 countries and products available in 180 markets.

About Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2013, the Group achieved net sales of USD 57.9 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 135,000 full-time-equivalent associates and sell products in more than 150 countries around the world.

1. International Agency for the Prevention of Blindness (IAPB), Global Facts. http://www.iapb.org/vision-2020/global-facts [Accessed October 6, 2014]
2. World Health Organization. Vision 2020: The Right to Sight. http://www.who.int/mip2001/files/1994/Vision2020-TheRighttoSight.pdf [Accessed June 26, 2014]

Most Popular Now

Cannabis extract helps reset brain function in psy…

Research from King's College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with psyc...

New cancer treatment uses enzymes to boost immune …

Researchers at The University of Texas at Austin have developed a new approach to treating cancer using enzyme therapy. The enzyme, PEG-KYNase, does not directly kill can...

Bayer accelerates six new startups

Changing the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year. The young companies fr...

Novartis receives European Commission approval of …

Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pe...

Antioxidant reduces risk for second heart attack, …

Doctors have long known that in the months after a heart attack or stroke, patients are more likely to have another attack or stroke. Now, a paper in the Journal of the A...

Shire completes sale of oncology franchise

Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it has completed the sale of its Oncology franchise to Servier S.A.S. for $2.4 billion. The franchise includes the...

Novartis to divest the Sandoz US dermatology busin…

Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids po...

Tezepelumab granted Breakthrough Therapy Designati…

AstraZeneca and its partner Amgen Inc. (Amgen) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab...

Pfizer terminates domagrozumab (PF-06252616) clini…

Pfizer Inc. (NYSE: PFE) announced that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrop...

New tablet production facility in Ingelheim: Cente…

Boehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on ...

Study links widely-used drug azathioprine to skin …

A drug used to treat inflammatory bowel disease, arthritis and vasculitis as well as to prevent organ rejection in transplant patients has been identified as an important...

Pfizer and Astellas amend clinical research protoc…

Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced amendments to the protocols for two registratio...